xl102
exelixis
['solid tumor', 'xl102 ']
 shared his phase 1 dose-escalation and expansion-cohort study of the oral cdk7 inhibitor xl102 as a single-agent and in combination therapy in patients with advanced solid tumors at today's #asco22 poster session. check it out below: 
Patient-centered care, clinical trials & translational research on breast cancer @DanaFarber and @HarvardMed. Appts: 877-442-3324, Clinical trials: 877-338-7425